GlassScriptPhysician profile
Anne E Love
NPI 1861465197
$1,822.19
in general payments reported to CMS, 2019-2025
19 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $500 · 2023: $549 · 2024: $504 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $265.99 | 2022-2025 | |
| Pfizer INC. | $212.35 | 2022-2025 | |
| Lilly USA, LLC | $167.38 | 2022-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $114.85 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.21 | 2022-2025 | Jardiance |
| Abbott Laboratories | $98.37 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Biotech, INC. | $58.08 | 2025 | Tremfya |
| Mylan Specialty L.P. | $45.72 | 2023-2024 | Yupelri |
| Amgen INC. | $42.55 | 2022-2023 | Prolia, Evenity |
| Exact Sciences Corporation | $41.64 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $41.00 | 2022 | |
| Dexcom, INC. | $31.97 | 2022-2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $23.93 | 2025 | Inspire |
| Vbi Vaccine (Delaware) INC. | $18.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $16.73 | 2024 | Optimizer |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Bexsero |
| Astellas Pharma US INC | $16.50 | 2023 | Veozah |
| Ibsa Pharma INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.